Journal article
Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report
Curēus (Palo Alto, CA), Vol.15(12), e50112
12/07/2023
DOI: 10.7759/cureus.50112
PMCID: PMC10771104
PMID: 38186543
Abstract
Anaphylaxis is a rapid and severe reaction to a trigger that is characterized by skin, mucosal, and cardiorespiratory changes. A minority of patients exhibit a biphasic anaphylactic reaction (BAR). Tirzepatide is a dual incretin receptor analog approved for the treatment of type 2 diabetes mellitus (T2DM). Allergic reactions to tirzepatide were reported during clinical trials, but none were severe enough to be characterized as an anaphylactic reaction. We describe a case of a BAR to tirzepatide.
Details
- Title: Subtitle
- Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report
- Creators
- Zhexiang He - Conway Regional Health SystemAgborya N. Tabe - Conway Regional Health SystemSohaib Rana - Conway Regional Health SystemKristy King - Conway Regional Health System
- Resource Type
- Journal article
- Publication Details
- Curēus (Palo Alto, CA), Vol.15(12), e50112
- DOI
- 10.7759/cureus.50112
- PMID
- 38186543
- PMCID
- PMC10771104
- NLM abbreviation
- Cureus
- ISSN
- 2168-8184
- eISSN
- 2168-8184
- Publisher
- Springer Nature
- Number of pages
- 4
- Language
- English
- Date published
- 12/07/2023
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984845469302771
Metrics
39 Record Views